BELGIUM – Ghent, 21 February 2023: Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of Continuous Metabolite Monitoring (CMM®) devices utilising proprietary nanophotonics technology, today announces that that an abstract featuring its CMM® sensor has been selected for oral/poster presentation at the upcoming 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) meeting which will be held from 22-25 February 2023 in Berlin, Germany.
Claudio Cobelli, Emeritus Professor of Bioengineering, The Department of Woman and Child’s Health, University of Padova, Italy and Dr Alfonso Galderisi, The Department of Woman and Child’s Health, University of Padova, Italy and The Department of Pediatrics, Yale University, New Haven, CT, USA, authors, will present the poster which is entitled “Beyond the glucose-centric diabetes management: the path to multiple sensing.”
A pre-recorded audio file of a poster presentation on the GLOW study from Francesca De Ridder, PhD Student / Medical Resident Internal Medicine, will also be available during the conference.
Further details are below:
Title: Beyond the glucose-centric diabetes management: the path to multiple sensing
Presenting Author: Professor Claudio Cobelli and Dr Alfonso Galderisi
Session: Emerging Technologies in Diabetes session
Date and Time: 13:45 CET (local time) on Saturday 25th February 2023
Title: First-in-man early feasibility study with an implantable sensor for continuous monitoring of glucose, ketones, lactate and ethanol via near-infrared spectroscopy: The GLOW Study
Pre-recorded Author: Francesca De Ridder, PhD Student / Medical Resident Internal Medicine
Dr. Danaë Delbeke, CEO, Inventor and Co-founder of Indigo Diabetes, commented: “These interesting new data underscore the importance of measuring real time lactate and ketones levels as key metabolites, important for the wellbeing of people living with diabetes. These may pave the way for a new generation of automated insulin delivery systems (AID), able to minimize the need for manual insulin delivery by the user and to broaden the use of AID to other clinical settings.”
Indigo is developing a fully implantable CMM system for people living with diabetes to access accurate information on their glucose, ketones and lactate levels. The CMM sensor is inserted subcutaneously, avoiding the need for people with diabetes to wear an external device on their body. It is designed to give people living with diabetes and their caregivers instant access to the augmented metabolic information they need to better manage their diabetes and improve therapeutic decision-making.
-ENDS-
Contacts
Indigo Diabetes N.V.
Dr Danaë Delbeke, CEO
Email: info@indigomed.com
Consilium Strategic Communications
Ashley Tapp, Alexandra Harrison
Tel: +44 (0)20 3709 5700
Email: indigodiabetes@consilium-comms.com
About Indigo Diabetes N.V.
Indigo Diabetes N.V. (Indigo) is a pioneering developer of medical devices that utilise proprietary nanophotonics technology. Indigo was founded by Danaë Delbeke and her team in 2016. Today Indigo is developing the world’s first subcutaneously inserted sensor for people living with diabetes to address their need for continuous accurate glucose, ketone and lactate monitoring with nothing worn on the body. Indigo utilizes ground-breaking photonics technology to transform diabetes management. Indigo is based in Ghent, Belgium. Find out more at www.indigomed.com.
About Indigo Diabetes’s CMM™ sensor
Indigo Diabetes’s CMM™ sensor is the world’s first, subcutaneously inserted evanescent field sensor to measure multiple metabolites in vivo simultaneously and continuously. The inert, miniature integrated silicon photonics chip measures the absorption of light in interstitial fluid to quantify the concentration of a broad range of metabolites simultaneously without the use of enzymes or fluorophores. Once inserted under the skin the CMM sensor is invisible to the naked eye and will connect securely and wirelessly to mobile devices to show and capture the concentration profiles of the metabolites for the user. A rechargeable sensor battery powers the measurements. It is expected that the sensor will have a lifetime up to 2 years. Preclinical studies have successfully demonstrated proof of concept with promising accuracy.
About the GLOW study
The GLOW clinical trial was a prospective, single-center early feasibility study conducted at the Antwerp University Hospital, Belgium to evaluate the safety of Indigo’s CMM sensor and its short-term integration into the tissue. Data was collected from the seven trial participants (three healthy subjects, and four subjects with type 1 diabetes) and the results have helped progress the development of the device to allow real-time, continuous measurement of glucose, ketone, and lactate levels in adults with diabetes.
About the ATTD
The International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) was established in 2008 and has held annual meetings since then. The purpose of the ATTD meeting is to highlight innovative technologies in diabetes treatment. It brings together developers of new technologies with the diabetes professionals and caretakers as well as acquainting clinicians with techniques for new treatments. Further information about the conference can be found online at https://attd.kenes.com/